X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GLENMARK PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GLENMARK PHARMA ASTRAZENECA PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 105.3 11.9 882.5% View Chart
P/BV x 15.0 3.2 475.8% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
GLENMARK PHARMA
Mar-17
ASTRAZENECA PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285993 129.4%   
Low Rs634729 86.9%   
Sales per share (Unadj.) Rs189.6325.5 58.2%  
Earnings per share (Unadj.) Rs-0.239.3 -0.5%  
Cash flow per share (Unadj.) Rs3.848.7 7.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs68.6159.2 43.1%  
Shares outstanding (eoy) m25.00282.17 8.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.12.6 191.3%   
Avg P/E ratio x-4,712.721.9 -21,503.6%  
P/CF ratio (eoy) x249.617.7 1,410.4%  
Price / Book Value ratio x14.05.4 258.4%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m23,988242,991 9.9%   
No. of employees `0001.613.0 12.0%   
Total wages/salary Rs m1,60516,408 9.8%   
Avg. sales/employee Rs Th3,040.27,083.9 42.9%   
Avg. wages/employee Rs Th1,029.21,265.4 81.3%   
Avg. net profit/employee Rs Th-3.3855.1 -0.4%   
INCOME DATA
Net Sales Rs m4,74091,857 5.2%  
Other income Rs m92374 24.6%   
Total revenues Rs m4,83292,230 5.2%   
Gross profit Rs m-13020,367 -0.6%  
Depreciation Rs m1012,644 3.8%   
Interest Rs m02,373 0.0%   
Profit before tax Rs m-13915,724 -0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139-810 -17.2%   
Tax Rs m53,827 0.1%   
Profit after tax Rs m-511,088 -0.0%  
Gross profit margin %-2.722.2 -12.4%  
Effective tax rate %-3.724.3 -15.1%   
Net profit margin %-0.112.1 -0.9%  
BALANCE SHEET DATA
Current assets Rs m2,72668,746 4.0%   
Current liabilities Rs m2,43527,027 9.0%   
Net working cap to sales %6.145.4 13.5%  
Current ratio x1.12.5 44.0%  
Inventory Days Days7485 86.8%  
Debtors Days Days4196 42.7%  
Net fixed assets Rs m1,03524,132 4.3%   
Share capital Rs m50282 17.7%   
"Free" reserves Rs m94244,643 2.1%   
Net worth Rs m1,71644,925 3.8%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m4,156117,639 3.5%  
Interest coverage xNM7.6-  
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.10.8 146.1%   
Return on assets %-0.111.4 -1.1%  
Return on equity %-0.324.7 -1.2%  
Return on capital %019.1 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37556,152 0.7%   
Fx outflow Rs m4708,084 5.8%   
Net fx Rs m-9648,068 -0.2%   
CASH FLOW
From Operations Rs m-86,574 -0.1%  
From Investments Rs m-146-7,124 2.0%  
From Financial Activity Rs m8625,432 15.9%  
Net Cashflow Rs m7091,992 35.6%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 6.9 4.3%  
FIIs % 15.7 34.4 45.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   12,856 56,727 22.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  SUVEN LIFE  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS